Screener
Collegium Pharmaceutical, Inc. COLL Symproic and other — 2027
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.
The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:34 AM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-011992
| Years ended December 31, | Jornay PM | Belbuca | Nucynta Products | Symproic | Total |
|---|---|---|---|---|---|
| 2026 | $83,829 | $75,393 | $27,692 | $7,285 | $194,199 |
| 2027 | 83,829 | — | — | 7,285 | 91,114 |
| 2028 | 83,829 | — | — | 7,285 | 91,114 |
| 2029 | 83,829 | — | — | 7,285 | 91,114 |
| 2030 | 83,829 | — | — | 7,285 | 91,114 |
| Thereafter | 104,783 | — | — | 6,072 | 110,855 |
| Remaining amortization expense | $523,928 | $75,393 | $27,692 | $42,497 | $669,510 |
Item 16. Form 10-K Summary
FAQ
- What is Collegium Pharmaceutical, Inc.'s symproic and other — 2027?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — 2027 of $7.29M in Q4 2025.
- What does symproic and other — 2027 mean?
- Represents the projected or actual financial performance metric for the Symproic segment specifically for the fiscal year 2027. It is used by investors to model the sustainability and growth trajectory of the product line beyond the immediate term.
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — 2027.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude